Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blind, placebo-controlled study with two weeks of daily oral
administration of one of three dose levels of Paxerol or placebo in subjects with nocturia.
Eligible study subjects will be identified according to inclusion/exclusion criteria (see
below), and baseline assessments will be recorded.
Due to small sample size of 25 patients per group in this proof-of-principle dosing-finding
trial, stratification according to gender and BMI will be difficult. However, similar
distribution of patient types to the four treatment groups will be attempted by evenly
assigning patients to the four treatment groups according to genders and body mass index
(BMI) of <25, 25-30 and 30-40.
Paxerol or placebo will be taken 30 minutes before bedtime daily for two weeks. Nocturia
frequency, Nocturia Quality of Life (NQOL), Duration of First Undisturbed Sleep (DFUS), total
hours of nightly sleep, safety and tolerability will be monitored before and after a two-week
treatment period. Results from subjects treated with different doses of Paxerol and placebo
will be assessed and compared. Baseline urinary Prostaglandin E2 (PGE2) production will also
be assayed to assess potential correlation between baseline urinary PGE2 production and
responsiveness to Paxerol treatment.